Puneeth Iyengar
Radiation Oncology · Dallas, TXNPI 1205168887
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by AstraZeneca at 46.0% of the total. 2025 is the largest year on record at $17,383, more than ten times the $1,562 reported in 2019. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $752.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Astrazeneca UK Limited$9K
- Pfizer$9K
- E.r. Squibb & Sons, L.L.C.$7K
- Novocure Inc.$4K
- Johnson & Johnson$2K
- plus $2K from 6 others
Across 31 payments — averaging $16,414 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$257K
- AstraZeneca$252K
What the payments were for
- Consulting fees$33,14655%
- Speaking & faculty fees$19,43032%
- Travel & lodging$4,0127%
- Food & beverage$3,6496%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $27,717 |
| Astrazeneca UK Limited | 12 | $8,759 |
| Pfizer | 4 | $8,755 |
| E.r. Squibb & Sons, L.L.C. | 2 | $6,750 |
| Novocure Inc. | 6 | $4,226 |
| Johnson & Johnson | 2 | $1,977 |
| GE HealthCare | 4 | $1,355 |
| Siemens Medical Solutions USA, Inc. | 2 | $265 |
| Viewray Technologies Inc | 1 | $198 |
| Tempus AI, Inc | 7 | $181 |
| Genentech, Inc. | 1 | $38 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$9,758
- LORBRENA$6,200
- XALKORI$6,200
- IMFINZI$4,540
- OPTUNE LUA (NOVOTTF-200T)$4,085
- VIZIMPRO$3,700
- MEKTOVI$3,700
- BRAFTOVI$3,700
- RYBREVANT$1,977
- MRIdian LINAC$198
- Varian Treatment$139
- ONGLYZA$131
How this compares
$60,238 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 12 | $190 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Dallas
- Hak ChoyDallas$119K
- Robert TimmermanDallas$77K
- Assal RahimiDallas$43K
- Neil DesaiDallas$29K
- Kiran KumarDallas$29K
- Kenneth WestoverDallas$24K
- Jonathan VermaDallas$6K
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.